BOD Science Ltd (BOD) - Total Assets
Based on the latest financial reports, BOD Science Ltd (BOD) holds total assets worth AU$2.60 Million AUD (≈ $1.84 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See what is BOD Science Ltd's book value for net asset value and shareholders' equity analysis.
BOD Science Ltd - Total Assets Trend (2016–2025)
This chart illustrates how BOD Science Ltd's total assets have evolved over time, based on quarterly financial data.
BOD Science Ltd - Asset Composition Analysis
Current Asset Composition (June 2025)
BOD Science Ltd's total assets of AU$2.60 Million consist of 99.9% current assets and 0.2% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 42.3% |
| Accounts Receivable | AU$168.02K | 6.5% |
| Inventory | AU$408.46K | 15.7% |
| Property, Plant & Equipment | AU$0.00 | 0.0% |
| Intangible Assets | AU$3.13K | 0.1% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how BOD Science Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of BOD Science Ltd.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BOD Science Ltd's current assets represent 99.9% of total assets in 2025, a decrease from 100.0% in 2016.
- Cash Position: Cash and equivalents constituted 42.3% of total assets in 2025, down from 99.4% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is inventory at 15.7% of total assets.
BOD Science Ltd Competitors by Total Assets
Key competitors of BOD Science Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
China | CN¥68.33 Billion |
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr67.43 Billion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC
|
USA | $5.76 Million |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Henan Newland Pharmaceutical Co. Ltd. A
SHE:301277
|
China | CN¥1.77 Billion |
BOD Science Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.34 | 0.30 | 2.21 |
| Quick Ratio | 0.28 | 0.21 | 2.08 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | AU$-5.10 Million | AU$-5.30 Million | AU$4.61 Million |
BOD Science Ltd - Advanced Valuation Insights
This section examines the relationship between BOD Science Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.45 |
| Latest Market Cap to Assets Ratio | 1.16 |
| Asset Growth Rate (YoY) | 12.6% |
| Total Assets | AU$2.60 Million |
| Market Capitalization | $3.01 Million USD |
Valuation Analysis
Above Book Valuation: The market values BOD Science Ltd's assets above their book value (1.16x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: BOD Science Ltd's assets grew by 12.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for BOD Science Ltd (2016–2025)
The table below shows the annual total assets of BOD Science Ltd from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$2.60 Million ≈ $1.84 Million |
+12.59% |
| 2024-06-30 | AU$2.31 Million ≈ $1.63 Million |
-34.16% |
| 2023-06-30 | AU$3.50 Million ≈ $2.48 Million |
-34.06% |
| 2022-06-30 | AU$5.31 Million ≈ $3.76 Million |
-48.67% |
| 2021-06-30 | AU$10.35 Million ≈ $7.32 Million |
+16.14% |
| 2020-06-30 | AU$8.91 Million ≈ $6.31 Million |
+155.28% |
| 2019-06-30 | AU$3.49 Million ≈ $2.47 Million |
-8.84% |
| 2018-06-30 | AU$3.83 Million ≈ $2.71 Million |
+6.17% |
| 2017-06-30 | AU$3.61 Million ≈ $2.55 Million |
-35.85% |
| 2016-06-30 | AU$5.62 Million ≈ $3.98 Million |
-- |
About BOD Science Ltd
Bod Science Limited operates as a cannabis focused drug development and product innovation company in Australia, the United Kingdom, the European Union, and the United States. The company operates through four segments: Medical, Over The Counter (OTC) Cannabidiol/Hemp, OTC Herbals, and Corporate. It engages in the development of cannabidiol and hemp products for consumers; and development and dis… Read more